NCT02645149 2026-02-27
Match Mel
Melanoma Institute Australia
Phase 2 Completed
Clinical Trials
32 trialsNCT03501368 2026-02-27
Study of Trametinib + Ceritinib in Patients With Unresectable Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT04961619 2025-12-12
LEAD Melanoma
Novartis
Completed
NCT05668585 2025-11-21
A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid Tumors
C4 Therapeutics, Inc.
Phase 1 Completed
NCT03551626 2025-04-29
COMBI-APlus
Novartis
Phase 3 Completed
NCT03944356 2025-03-12
Combi-EU
EuMelaReg gGmbH
Completed
NCT03026517 2025-01-23
Clinical Trial of Phenformin in Combination With BRAF Inhibitor + MEK Inhibitor for Patients With BRAF-mutated Melanoma
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT01902173 2025-01-14
Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT02872259 2025-01-14
BGB324 in Combination With Pembrolizumab or Dabrafenib/Trametinib in Metastatic Melanoma
Haukeland University Hospital
Phase 1/2 Completed
NCT02392871 2024-11-27
CombiRT
Melanoma and Skin Cancer Trials Limited
Phase 1/2 Completed
NCT04059224 2023-09-26
TraMel-WT
Universitair Ziekenhuis Brussel
Phase 2 Completed
NCT01682083 2023-08-30
COMBI-AD
Novartis
Phase 3 Completed
NCT04547946 2023-05-30
Observational Study for Melanoma Adjuvant Treatment With Tafinlar® + Mekinist® (Dabrafenib + Trametinib)
Novartis
Completed
NCT02130466 2022-08-01
MK-3475-022
Merck Sharp & Dohme LLC
Phase 1/2 Completed
NCT02083354 2022-02-01
Study to Investigate the Objective Response Rate of Dabrafenib in Combination With Trametinib in Subjects With BRAF V600 Mutation-Positive Melanoma
Novartis
Phase 2 Completed
NCT02296112 2021-05-28
Trametinib in Treating Patients With Advanced Melanoma With BRAF Non-V600 Mutations
Vanderbilt-Ingram Cancer Center
Phase 2 Completed
NCT02110355 2021-03-26
A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma
Kartos Therapeutics, Inc.
Phase 1 Completed
NCT01584648 2021-02-17
A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma
Novartis
Phase 3 Completed
NCT03352947 2020-12-08
INTERIM
Cambridge University Hospitals NHS Foundation Trust
Phase 2 Completed
NCT01941927 2020-02-12
Trametinib With GSK2141795 in BRAF Wild-type Melanoma
University of California, San Francisco
Phase 2 Completed
NCT02439411 2019-12-02
DEIS
Grupo Español Multidisciplinar de Melanoma
Completed
NCT01072175 2019-07-05
Investigate Safety, Pharmacokinetics and Pharmacodynamics of GSK2118436 & GSK1120212
Novartis
Phase 2 Completed
NCT02039947 2019-05-21
Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain
Novartis
Phase 2 Completed
NCT02027961 2019-05-17
Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone
MedImmune LLC
Phase 1 Completed
NCT02296996 2019-01-23
Dabrafenib and Trametinib for BRAF-inhibitor Pretreated Patients
Universitair Ziekenhuis Brussel
Phase 2 Completed
NCT02065063 2018-06-01
A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Anti-Cancer Activity of Trametinib in Combination With Palbociclib in Subjects With Solid Tumors
GlaxoSmithKline
Phase 1 Completed
NCT02138292 2018-05-15
A Phase 1B Clinical Trial of Trametinib Plus Digoxin in Patients With Unresectable or Metastatic BRAF Wild-type Melanoma
University of Texas Southwestern Medical Center
Phase 1 Completed
NCT01245062 2018-04-05
GSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma
GlaxoSmithKline
Phase 3 Completed
NCT01767454 2017-11-14
Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma
GlaxoSmithKline
Phase 1 Completed
NCT00687622 2017-11-13
Open-label Study to Investigate the Safety, PK, and Pharmacodynamics of GSK1120212 in Subjects With Solid Tumors or Lymphoma
GlaxoSmithKline
Phase 1 Completed
NCT01928940 2017-07-24
Japan PhI/II of GSK2118436 and GSK1120212 Combination in Subjects With BRAF V600E/K Mutation Positive Advanced Solid Tumors (Phase I Part) or Cutaneous Melanoma (Phase II Part)
GlaxoSmithKline
Phase 2 Completed
NCT01619774 2016-12-12
An Open-Label Phase II Study of the Combination of GSK2118436 and GSK1120212 in Patients With Metastatic Melanoma Which is Refractory or Resistant to BRAF Inhibitor
M.D. Anderson Cancer Center
Phase 2 Completed